Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADAM17 | P78536 | 1/20 | 0.50 |
| ▸ | CCR1 | P32246 | 1/20 | 0.49 |
| ▸ | NPC1 | O15118 | 5/20 | 0.45 |
| ▸ | RAB9A | P51151 | 4/20 | 0.45 |
| ▸ | MEN1 | O00255 | 2/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.45 |
| ▸ | CASP3 | P42574 | 1/20 | 0.45 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.45 |
| ▸ | DEGS1 | O15121 | 1/20 | 0.45 |
| ▸ | DRD4 | P21917 | 1/20 | 0.45 |
| ▸ | PIN1 | Q13526 | 2/20 | 0.44 |
| ▸ | UTS2R | Q9UKP6 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.44 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.44 |
| ▸ | CASP1 | P29466 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4448270 | 1.00 | ADAM17 (0.50) | ADAM17CCR1NPC1RAB9AMEN1 | |
| SCHEMBL4450252 | 0.84 | NPC1 (0.47) | NPC1RAB9A | |
| SCHEMBL4450260 | 0.84 | NPC1 (0.47) | NPC1RAB9A | |
| SCHEMBL4445027 | 0.82 | HPGDS (0.59) | NPC1RAB9A | |
| SCHEMBL4445032 | 0.82 | HPGDS (0.59) | NPC1RAB9A | |
| SCHEMBL4456911 | 0.81 | KDM4E (0.55) | CCR1NPC1UTS2RKDM4E | |
| SCHEMBL4456912 | 0.81 | KDM4E (0.55) | CCR1NPC1UTS2RKDM4E | |
| SCHEMBL4456908 | 0.81 | KMT2A (0.49) | NPC1KMT2A | |
| SCHEMBL4456906 | 0.81 | KMT2A (0.49) | NPC1KMT2A | |
| SCHEMBL4454228 | 0.81 | ALDH1A1 (0.54) | NPC1RAB9AMEN1KMT2ACASP3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090012010-A1 | Amino acid derivatives as calcium channel blockers | NEUROMED PHRAMACEUTICALS LTD. (CA) | 2009-01-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090012010-A1 | Amino acid derivatives as calcium channel blockers | CACNA1G, CACNA1H, CACNA1I | ADAM17 3570/4885CCR1 4099/4885NPC1 2098/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.